Cognition Therapeutics, Inc.

NASDAQ:CGTX

Biotechnology

Healthcare
$0.60 -0.70%

-$0.01 today

Market cap
$57.06M
Beta
1.75
P/E (TTM)
-6.4
EPS (TTM)
-$0.22
52W Low $0.25High $3.83

Volume 0.34M

Average 1.23M

CGTX Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Cognition Therapeutics, Inc.NASDAQ: CGTX

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash dips below year-ago levels

Q1 FY2026 net change in cash of $5.78M (cash outflow) fell 32.7% year over year, behind the +181.1% change in trailing-twelve-month net change in cash. Sequentially, it rose 104.6% from the prior quarter.

Context

  • Net change in cash increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -32.7% toward the trailing-twelve-month pace of +181.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.78M+104.6% QoQ
Last fiscal yearDec 2025
$11.99M+344.1% YoY
LTMMar 2026
$14.8M+181.1% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-32.7%——
1 year+344.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
11.99M USD
Year-over-year change
+344.1%
4-year CAGR
-29.9%

Net Change in Cash vs competitors

How CGTX compares with its peers on the latest reported figures

  • CGTX's LTM Mar 2026 net change in cash of $14.8M is the 3rd largest of the 8 companies compared; the peer median is $7.24M.
  • Its year-over-year change of +181.1% is the 3rd highest of 8, against a peer median of +142.4%.
CGTX Competitors Peer median
Net Change in Cash for CGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MCRBSeres Therapeutics, Inc.LTM Mar 2026$29.02M -44.3%—2529.6%
IRDOpus Genetics, Inc.LTM Mar 2026$18.17M +438.4%-6.6%151.6%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$14.8M +181.1%——
AGENAgenus Inc.LTM Mar 2026$14.59M +142.4%-31.9%11.8%
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$7.76M +381.4%——
SPROSpero Therapeutics, Inc.LTM Mar 2026$7.24M +121.7%+53.7%13.2%
SRZNSurrozen, Inc.LTM Mar 2026$5.27M -92.9%—70.3%
SEERSeer, Inc.LTM Mar 2026$5.13M +162.5%—34.1%
Peer median (excluding CGTX) $7.24M+142.4%-6.6%52.2%

Competitors are the stored peer set for CGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(11.72M)(21.4M)(25.79M)(33.97M)(23.49M)
Depreciation & Amortization93K235K252K266K228K
Deferred Income Tax00000
Stock-Based Compensation5.18M3.57M4.35M3.75M2.09M
Change in Working Capital2.84M(943K)4.85M1.29M(3.46M)
Accounts Receivables(1.11M)(1.41M)2.39M(1.41M)(7.24M)
Inventory00000
Accounts Payables2.17M(1.09M)003.51M
Other Working Capital1.79M1.56M2.46M2.69M270K
Other Non-Cash Items(33K)0318K195K41K
Operating Cash Flow(3.63M)(18.53M)(16.02M)(28.47M)(24.59M)
Capital Expenditures(27K)(171K)(147K)(4K)0
Acquisitions (Net)00009K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(27K)(171K)(147K)(4K)9K
Debt Repayment(268K)(1.4M)(811K)(739K)(353K)
Common Stock Issued44.22M5.32M5.33M24.35M37.09M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.25M1.62M0(46K)(164K)
Financing Cash Flow53.2M5.55M4.52M23.57M36.57M
Effect of Forex Changes(11K)(1K)4K00
Net Change in Cash49.53M(13.16M)(11.64M)(4.91M)11.99M
Free Cash Flow(3.66M)(18.7M)(16.17M)(28.48M)(24.59M)

Cognition Therapeutics, Inc.

NASDAQ:CGTX

Intrinsic Alpha fair value

Locked

Current Price

$0.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.